Home
Charts
Search
Watchlist
Products
All IPOs
₹79 - 79
Gaudium IVF and Women Health Ltd
HealthcareIPO
₹79 - 79
The company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Hub and spoke model over the years. Gaudium IVF is founded by our Promoter Dr. Manika Khanna, a specialist with advanced training in gynecological endoscopic surgery from Kiel, Germany, and in Gynaec Endoscopy from Melbourne IVF Gujarat Private Limited. The company operates 30+ locations, which comprises of 7 hubs (centers) and 28 spokes (company has entered into a strategic alliance with Spokes i.e Infertility Expert to achieve the mutual goal of spreading awareness about ART and IVF treatment). Its treatments include In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI) and ovulation induction, all its treatment is carefully designed to address a variety of infertility challenges for both male and female.
Lot189Min Invest₹14,931Face Value₹5Issue Size₹165 CrFresh Issue₹90 CrOffer for Sale₹75 CrListing Price₹83CMP₹92
Timeline
20 Feb
Bidding opens
24 Feb
Bidding closes
25 Feb
Allotment
25-26 Feb
Refund & demat credit
27 Feb
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹165 Cr2.09 Cr shares
Fresh Issue₹90 Cr
Offer for Sale₹75 Cr
Face Value₹5
Lot Size189 shares
ReservationQIB 50% · NII 15% · RETAIL 35%
Application Sizes
Retail₹14,9311-13 lots
sNII₹2,09,034from 14 lots
bNII₹10,00,377from 67 lots
Managers & Registrar
Lead ManagerSarthi Capital Advisors Pvt Ltd
RegistrarBigshare Services Pvt Ltd
Ownership & Proceeds
Offer for Sale
Selling ShareholderShares OfferedAmt ₹ CrManika KhannaPRMTR94,93,70075.00Total94,93,70075.00
Shareholding
CategoryPre IPOPost IPOPromoter Group99.98%71.3%Public0.02%28.7%
Objects of the Issue
- Funding capital expenditure towards establishment of new IVF centers of the company
- Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company
- Investment in the company wholly owned subsidiary (WOS), EKK global Pvt Ltd for - Launching of FMCG products
- Investment in the company wholly owned subsidiary (WOS), EKK global Pvt Ltd for - Funding its working capital requirements
- General corporate purposes
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| RevenueCr | 44 | 53 | 71 | 104 | 106 |
| Operating ProfitCr | 20 | 26 | 29 | 38 | 35 |
| OPM% | 45.4 | 47.8 | 40.5 | 36.1 | 32.9 |
| PBTCr | 18 | 23 | 25 | 32 | 31 |
| PATCr | 14 | 17 | 19 | 24 | 23 |
| EPS | 2 | 3 | 3 | 4 | 4 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| Equity CapitalCr | 1 | 1 | 31 | 36 | - |
| ReservesCr | 22 | 32 | 16 | 116 | - |
| BorrowingsCr | 12 | 17 | 21 | 25 | - |
| Fixed AssetsCr | - | - | 26 | 30 | - |
| Total AssetsCr | 37 | 57 | 89 | 193 | - |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 | Latest |
|---|---|---|---|---|---|
| Operating Cash FlowCr | 24 | 3 | 9 | 7 | - |
| Investing Cash FlowCr | -16 | -5 | -15 | -88 | - |
| Financing Cash FlowCr | 5 | -1 | 2 | 82 | - |
| Net Cash FlowCr | 13 | -3 | -5 | 2 | - |
Strengths & Risks
Strengths · as stated in the DRHP
- Clinical excellence and advanced medical technologies to deliver quality healthcare.
- Ability to attract, train and retain high-quality doctors and staff.
- Scalable model and disciplined approach for growth.
- Stable and robust financial performance.
- Professional management and experienced leadership of our Promoters i.e., Manika Khanna and Peeyush Khanna.
Strategies · as stated in the DRHP
- Establishment of New IVF Centers.
Risks · as stated in the DRHP
- The Company is in engaged in the business of providing healthcare services mainly rendering various fertility treatments such as In Vitro Fertilization (IVF), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), Egg Freezing, laser assisted embryo implantation amongst others and is subject to various operational, reputational, medical and legal risks associated with the operations of healthcare services. An inability to provide quality healthcare catering to the needs of the customers could adversely affect the reputation, business prospects and financial performance of the Company.
- The Company may highly dependent on doctors, nurses and other healthcare professionals and the business will be impacted significantly if the Company is unable to attract / retain such professionals.
- The business of the Company depends on the strength of the brand and reputation of the Company. Failure to maintain and enhance the brand and reputation, and any negative publicity and allegations in the media against the Company, even if untrue, may adversely affect the brand, reputation and trust in, services of the Company, which could result in a material adverse impact on business, financial condition, results of operations and prospects of the Company.
- The Company may face challenges in further expanding operations in cities where the Company currently operate in or in other cities that the Company strategically intend to commence operations, which could have an adverse effect on the business prospects and future financial performance.
- Our Company has experienced negative cash flows in the past. We cannot assure you that we will achieve or sustain profitability and not continue to incur losses going forward.
- The failure to identify, understand and adapt to rapidly evolving technological advancements related to our medical equipment and technology could adversely affect our business prospects and financial performance.